<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04819464</url>
  </required_header>
  <id_info>
    <org_study_id>ID-064-106</org_study_id>
    <secondary_id>2020-006002-23</secondary_id>
    <nct_id>NCT04819464</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod</brief_title>
  <official_title>An Open-label, Parallel-group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cenerimod After Single-dose Administration in Subjects With Hepatic Impairment and in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, single-dose, phase 1 study, to assess the effect of mild&#xD;
      and moderate hepatic impairment on the pharmacokinetics of cenerimod (ACT-334441).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The 3 groups will be sequentially studied. Dosing will start in the participants with mild hepatic impairment.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curves (AUC0-t): cenerimod</measure>
    <time_frame>Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from zero to infinity (AUC0-inf): cenerimod</measure>
    <time_frame>Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax): cenerimod.</measure>
    <time_frame>Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach Cmax (tmax): cenerimod</measure>
    <time_frame>Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half-life (tÂ½): cenerimod</measure>
    <time_frame>Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma protein binding of cenerimod</measure>
    <time_frame>Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent clearance (CL/F) of cenerimod</measure>
    <time_frame>Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution (Vz/F) of cenerimod</measure>
    <time_frame>Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 98.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total lymphocyte count</measure>
    <time_frame>Multiple sampling at predefined times on Day 1 (pre-dose) up to Day 98.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at each time point of measurement in electrocardiogram QT interval</measure>
    <time_frame>Pre-defined times on Day 1 (pre-dose) up to Day 105.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>Day -1 and Day 105.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in systolic and diastolic blood pressure (in the supine position)</measure>
    <time_frame>Predefined times on Day 1 (pre-dose) up to Day 105.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of abnormal laboratory test results</measure>
    <time_frame>Multiple sampling at predefined times on Day 1 (pre-dose) up to Day 105.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and serious adverse events</measure>
    <time_frame>Day 1 up to Day 105.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy</condition>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Group A: Participants with mild hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mild hepatic impairment (Child-Pugh Score of 5 to 6).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Participants with moderate hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate hepatic impairment (Child-Pugh Score of 7 to 9).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C:Healthy participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants will be matched to the participants with hepatic impairment based on age and body weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cenerimod</intervention_name>
    <description>A single oral dose of 0.5 mg.</description>
    <arm_group_label>Group A: Participants with mild hepatic impairment</arm_group_label>
    <arm_group_label>Group B: Participants with moderate hepatic impairment</arm_group_label>
    <arm_group_label>Group C:Healthy participants</arm_group_label>
    <other_name>ACT-334441</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent in a language understandable to the participant prior to any&#xD;
             study-mandated procedure.&#xD;
&#xD;
          -  Women of child bearing potential must have a negative serum pregnancy test at&#xD;
             screening, a negative urine pregnancy test on Day -1, and must agree to consistently&#xD;
             and correctly use a highly effective method of contraception (i.e., failure rate of&#xD;
             less than 1%).&#xD;
&#xD;
          -  Women of non-childbearing potential must have a medical history of previous bilateral&#xD;
             salpingectomy, salpingo-oophorectomy or hysterectomy, premature ovarian failure&#xD;
             confirmed by a specialist gynecologist; or, be post-menopausal, defined as 12&#xD;
             consecutive months with amenorrhea prior to screening without alternative medical&#xD;
             cause and confirmed with a follicle-stimulating hormone test.&#xD;
&#xD;
          -  Body mass index of 18.0 to 32.0 kg/m2 (inclusive) at screening.&#xD;
&#xD;
          -  Negative SARS-CoV-2-testing prior to Day -1 or documented vaccination against COVID-19&#xD;
             at least 3 months prior screening.&#xD;
&#xD;
          -  Ability to communicate well with the investigator, in a language understandable to the&#xD;
             participant, and to understand and comply with the requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General (Group A, B and C)&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Participation in a clinical study involving study treatment administration within 30&#xD;
             days prior to screening or in more than 2 clinical studies within 1 year prior to&#xD;
             screening.&#xD;
&#xD;
          -  Previous exposure to cenerimod.&#xD;
&#xD;
          -  History or clinical evidence of any disease and/or existence of any surgical or&#xD;
             medical condition, which might interfere with the absorption, distribution,&#xD;
             metabolism, elimination (ADME) of the study treatment except for those related to&#xD;
             liver cirrhosis or appendectomy and herniotomy.&#xD;
&#xD;
          -  International Normalized Ratio greater than 2 at screening.&#xD;
&#xD;
          -  Encephalopathy grade greater than or equal to 1.&#xD;
&#xD;
          -  Clinically relevant abnormalities on a 12-lead ECG, recorded after 5 minutes in the&#xD;
             supine position at screening and on Day 1 pre-dose.&#xD;
&#xD;
          -  Presence of herpes simplex, disseminated zoster, or other opportunistic infections.&#xD;
&#xD;
          -  Vaccination with live or live attenuated vaccines in the previous 4 weeks.&#xD;
&#xD;
          -  Previous treatment with antiarrhythmic medications of class Ia or III 2 weeks or 5&#xD;
             half-lives, whichever is longer, prior to study treatment administration.&#xD;
&#xD;
          -  Active retinopathy or macular edema at screening.&#xD;
&#xD;
          -  Severe chronic obstructive pulmonary disease at screening.&#xD;
&#xD;
          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect&#xD;
             full participation in the study or compliance with the protocol.&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity at screening.&#xD;
&#xD;
        Additional inclusion criteria for participants with hepatic impairment (Group A and B)&#xD;
&#xD;
          -  Clinically relevant findings in clinical laboratory tests (hematology, coagulation,&#xD;
             clinical chemistry, and urinalysis) at screening and on Day -1, except for those&#xD;
             related to liver cirrhosis.&#xD;
&#xD;
        Additional exclusion criteria for healthy subjects (Group C)&#xD;
&#xD;
          -  Clinically relevant findings in clinical laboratory tests (hematology, coagulation,&#xD;
             clinical chemistry, and urinalysis) at screening and on Day -1.&#xD;
&#xD;
          -  Previous treatment with any prescribed medications (including vaccines) or OTC&#xD;
             medications (including herbal medicines such as St. John's Wort, homeopathic&#xD;
             preparations, vitamins, and minerals) within 2 weeks or 5 tÂ½ prior to study treatment&#xD;
             administration, whichever is longer (excluding contraceptives and HRT).&#xD;
&#xD;
          -  Aspartate aminotransferase and alanine aminotransferase above the upper limit of&#xD;
             normal.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Disclosure Desk</last_name>
    <phone>+41 58 844 1977</phone>
    <email>clinical-trials-disclosure@idorsia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>BlueClinical Phase 1 Hospital de Prelado</name>
      <address>
        <city>Porto</city>
        <zip>4250-449</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

